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It seems obvious that the 45 years of
experience in assessing the genetic hazards
from ionizing radiation can serve as a model
approach for assessing the vast world of
environmental mutagens. I am extremely
impressed with the three-tier approach sug-
gested by Bridges and also strongly feel that
it would be most useful to establish a roent-
gen equivalent mutagen dose estimate as
described by both Crow and Bridges. This at
least will permit assessing the mutagen in
terms of genetic risk to man. I should like to
point out the fact that in the past year both
the United Nations Scientific Committee
on the Effects of Atomic Radiation
(UNSCEAR) and the Biological Effects of
Ionizing Radiation (BEIR) committee of the
National Academy of Sciences have com-
pleted in depth and up-dated reports on gen-
etic risk estimates for man.
The problems and difficulties associated
with extrapolating the experimental data
to man and the necessary caveats involved
in so doing are documented in reports in the
preparation of which Drs. Crow, Wolff, and
E. B. Lewis have participated. I believe that
we would all agree that for all the uncer-
tainties, these estimates do provide us with
the most reasonable evaluations of hazard
that can be made from existing data.
Dr. Freese discussed the need for the
utilization of the concept of linearity in as-
sessing mutagenicity data; Dr. Nicols dis-
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cussed chromosome aberrations in man, Dr.
Lewis treated methods for assessing somatic
hazards, and Dr. Ramel touched on the need
for adequate training of qualified personnel
in carrying out mutagen testing and the pro-
blems associated in this area.
We opened up the discussion to all the
participants after each speaker had com-
pleted his presentation to permit considerable
exchange of views.
This was a truly stimulating discussion.
Many different viewpoints were expressed,
and I believe everyone had an opportunity
to make his views known.
Finally I should like to quote from the
genetics section of the BEIR committee re-
port on recommendations for estimating
genetic risks, which I think are particularly
relevant based on the present discussions:
1. "Use relevant data from all sources, but empha-
size human data when feasible. In general, when
data of comparable accuracy exist, place greater
emphasis on organisms closest to man."
2. "Use data from the lowest doses and dose rates
for which reliable data exist, as being more relevant
to the usual conditions of human exposure."
3. "Use simple linear extrapolation between the
lowest reliable dose data and the spontaneous or
zero dose rate. In order to get any kind of precision
from experiments of manageable size, it is necessary
to use dosages much higher than are expected for
the human population. Some mathematical assump-
tion is necessary and the linear model, if not always
correct. is likely to err on the safe side."
4. "If cell stages differ in serisitivity, weight the
data in accordance with the duration of the stage."
5. "If the sexes differ in sensitivity, use the un-
weighted average of data for the two sexes."
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